-+ 0.00%
-+ 0.00%
-+ 0.00%

ENHERTU® GRANTED BREAKTHROUGH THERAPY DESIGNATION IN THE U.S. AS POST-NEOADJUVANT THERAPY FOR PATIENTS WITH HER2 POSITIVE EARLY BREAST CANCER

Reuters·12/22/2025 07:30:00

Please log in to view news